Celltrion Launches Steqeyma in Europe

Celltrion has launched Steqeyma, its biosimilar version of Stelara (ustekinumab), in Germany as part of its strategy to establish a stronger presence in Europe’s autoimmune disease market. The company has prepared thoroughly, completing pricing approvals and setting up prescribing frameworks to ensure a smooth entry. Additionally, Celltrion has secured a critical procurement bid in the Netherlands that grants it access to nearly a third of the ustekinumab market there, positioning Steqeyma for rapid uptake.

Further releases are planned for Finland and Ireland, with Celltrion actively engaging with healthcare stakeholders and attending prominent medical events to promote Steqeyma. The company’s integrated manufacturing and sales approach aims to create a stable supply in Europe, leveraging this structure to expand its market share efficiently. Given the substantial $20.4 billion market for ustekinumab globally, Celltrion is intensifying efforts to extend Steqeyma’s availability across additional European countries next year.